Anchalee Avihingsanon, MD, PhD, HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand, is principal investigator of the ALLIANCE trial from Gilead.
The ALLIANCE trial from Gilead is investigating the triplet regimen of bictegravir/emtricitabine/tenofovir alafenamide (TAF) vs dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) among treatment-naïve persons living with comorbid HIV/hepatitis B virus (HBV). Anchalee Avihingsanon, MD, PhD, HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand, is the trial’s principal investigator.
Transcript
Can you discuss how the ALLIANCE trial addresses HIV/HBV coinfection overlapping risk factors and transmission patterns?
The literature shows a risk factor mainly from men having sex with men and intravenous drug users. In hep B, the main transmission is from the breath; [transmission] from sexual activity is very rare, but we have seen much higher [rates] among men having sex with men. For HIV and hepatitis B, they usually have a high hepatitis B, D, and A viral load. If you have such a high viral load, you can transmit the virus to others really easily like with HIV. I think we should use the term “treatment as prevention” as well. Hepatitis B has a vaccine to prevent infection, but in some groups, the vaccine doesn’t work or it doesn’t work quite well.
For this study, we know that the HIV suppression is very high for both TDF and TAF—and this is good for HIV. Even they have such high rates of HIV suppression, when you look at the hepatitis B, it’s only 60% for TAF and 40% for TDF. So there are some subpopulations that have [suboptimal] hepatitis B treatment, but we need longer follow-up to see whether the suppression will be higher on this or not.
For me, I think if we treat the patient so we can prevent transmission of this virus to others, if we use the most effective drug, then you can lower the viruses quicker.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Research Shows Prior Authorization Denials Delay Critical Immunology Care
May 10th 2024Results featured at the Academy of Managed Care Pharmacy 2024 annual meeting revealed a pattern of prior authorization rejections that could delay necessary therapeutic treatments for various patient groups.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More